Non-small cell lung cancer, ROS1-positive

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search


Section editor
TravisOsterman.jpg
Travis Osterman, DO, MS
Nashville, TN

Twitter: TravisOsterman
LinkedIn

Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.

2 regimens on this page
4 variants on this page


Advanced or metastatic disease, ROS1 inhibitor-naive

Ceritinib monotherapy

back to top

Regimen

Study Evidence Efficacy
Lim et al. 2017 Phase II ORR: 67% (95% CI, 48-81)

Chemotherapy

28-day cycles

References

  1. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017 Aug 10;35(23):2613-2618. Epub 2017 May 18. link to original article contains verified protocol PubMed

Crizotinib monotherapy

back to top

Variant #1, standard-dose

FDA-recommended dose
Study Evidence Efficacy
Shaw et al. 2014 Non-randomized ORR: 72% (95% CI, 58-84)

Note: this was an expansion cohort of a phase I study.

Chemotherapy

28-day cycles

Variant #2, 200 mg BID

FDA-recommended dose

Note: this is the FDA-recommended dosing for "moderate" hepatic impairment.

Chemotherapy

Given indefinitely

Variant #3, 250 mg/d

FDA-recommended dose

Note: this is the FDA-recommended dosing for "severe" hepatic or renal impairment.

Chemotherapy

Given indefinitely

References

  1. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71. Epub 2014 Sep 27. link to original article link to PMC article contains verified protocol PubMed

Additional resources

Investigational agents

Drugs with some degree of promising activity in clinical trials.